✦ LIBER ✦

Neuroprotective agents in Parkinson's disease: clinical evidence and caveats

✍ Scribed by Hälbig, Thomas D.; Tse, Winona; Olanow, C. Warren

Book ID: 122537283
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 248 KB
Volume: 22
Category: Article
ISSN: 0733-8619
DOI: 10.1016/j.ncl.2004.07.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroprotective agents for clinical tria

Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment

✍ Ravina, B.M.; Fagan, S.C.; Hart, R.G.; Hovinga, C.A.; Murphy, D.D.; Dawson, T.M. 📂 Article 📅 2003 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 338 KB

Clinical pharmacology and neuroprotectio

Clinical pharmacology and neuroprotection in Parkinson's disease

✍ Masahiro Nomoto 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Neuroprotection in Parkinson's disease:

Neuroprotection in Parkinson's disease: Clinical trials

✍ Fabrizio Stocchi; C. Warren Olanow 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 2 views

Parkinson's disease, insulin resistance

Parkinson's disease, insulin resistance and novel agents of neuroprotection

✍ Aviles-Olmos, I.; Limousin, P.; Lees, A.; Foltynie, T. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 440 KB

Neuroprotective clinical strategies for

Neuroprotective clinical strategies for Parkinson's disease

✍ Dr. Ira Shoulson 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB 👁 2 views

Neurotoxicological and neuroprotective e

Neurotoxicological and neuroprotective elements in Parkinson’s disease

✍ Richard M. Kostrzewa; Juan Segura-Aguilar 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 411 KB